Предыстория и актуальность
New trials and approvals of anti-HER2 agents have enriched the treatment options for HER2-positive early breast cancer. Escalation and de-escalation strategies are part of the treatment landscape.
Regulatory approval status of targeted therapies for early stage HER2-positive breast cancer (status 5 January 2024)